Alzhano Therapeutics targets the treatment of Tauopathies, a group of pathologies including Alzheimer’s disease as well as rare diseases, all currently untreated, with a best-in-class approach that aims to prevent the aggregation of Tau proteins in neuronal cells without destroying them.
Would you like to edit the information on your profile page?
Oops! We could not locate your form.